Radiation and immunotherapy team up against hard-to-treat lymphoma

NCT ID NCT07634289

First seen Jun 08, 2026 · Last updated Jun 12, 2026 · Updated 1 time

Summary

This study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments will receive radiation followed by 12 cycles of drug therapy. The main goal is to see how many patients achieve a complete response without severe side effects, with follow-up lasting up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Austin Hospital

    Heidelberg, Victoria, 3084, Australia

    Contact Email: •••••@•••••

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, 5042, Australia

    Contact Email: •••••@•••••

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102, Australia

    Contact Email: •••••@•••••

  • Townsville University Hospital

    Douglas, Queensland, Australia

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.